Beyond the biotech IPO: A brave new world

Nature Biotechnology

Volumn 27, Issue 8, 2009, Pages 705-709

  Booth, Bruce L ^a  

^a 400 Technology Square   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; DAPTOMYCIN; ECULIZUMAB; FERUMOXYTOL; KRYSTEXXA; NEW DRUG; SAVELLA; TELAPREVIR; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CAPITAL; CAREER; COMMERCIAL PHENOMENA; ECONOMIC CRISIS; FINANCIAL MANAGEMENT; FUNDING; INVESTMENT; NOTE; PRIORITY JOURNAL; RISK; STOCK MARKET; UNITED STATES;

BIOTECHNOLOGY; COMMERCE; DRUG INDUSTRY; MARKETING; ORGANIZATIONAL INNOVATION;

EID: 68549135134     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0809-705     Document Type: Note

References (3)

1. Mack, G. Nat. Biotechnol. 26, 960-961 (2008).
2. Licking, E.F. Startup 2-18 (May 2009).
3. Geilinger, U. & Leo, C. Trade Sales of Biotechnology and Specialty Pharma Companies 2005-2008 (HBM Partners, Zug, Switzerland, 2009)